Nuvation Bio Inc (NUVB)

$4.84 +0.08 (1.68%)
Market Cap 1.66B
Revenue (ttm) 62.90M
Net Income (ttm) -204.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -325.33%
Debt to Equity Ratio 0.17
Volume 2,540,700
Avg Vol 4,332,420
Day's Range N/A - N/A
Shares Out 348.20M
Stochastic %K 69%
Beta 1.51
Analysts Strong Sell
Price Target $12.55

Company Profile

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against place...

Industry: Biotechnology
Sector: Healthcare
Phone: 332 208 6102
Address:
1500 Broadway, Suite 1401, New York, United States
Bio_Invest101
Bio_Invest101 May. 11 at 6:59 PM
$NUVB Connor, Clark & Lunn Investment Management Ltd. reports 529.05% increase in ownership of NUVB / Nuvation Bio Inc. On May 11, 2026 - Connor, Clark & Lunn Investment Management Ltd. filed a 13F-HR form disclosing ownership of 1,207,771 shares of Nuvation Bio Inc. (US:NUVB) valued at $5,181,338 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 191,998 shares of Nuvation Bio Inc.. This represents a change in shares of 529.05% during the quarter. The current value of the position is $5,785,223 USD.
0 · Reply
SNOB_ORDER
SNOB_ORDER May. 11 at 6:23 PM
$NUVB Short Interest update (+330K) From 50,296,748 to 50,622,584
1 · Reply
Stevekill
Stevekill May. 11 at 4:59 PM
What’s up with this? $NUVB https://www.prnewswire.com/news-releases/shareholder-alert-purcell--lefkowitz-llp-announces-shareholder-investigation-of-nuvation-bio-inc-nyse-nuvb-302765701.html
2 · Reply
Bio_Invest101
Bio_Invest101 May. 11 at 2:56 PM
$NUVB again small but high percentage by a bank Citigroup Inc reports 400.58% increase in ownership of NUVB / Nuvation Bio Inc. On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 315,776 shares of Nuvation Bio Inc. (US:NUVB) valued at $1,354,679 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 63,082 shares of Nuvation Bio Inc.. This represents a change in shares of 400.58% during the quarter. The current value of the position is $1,512,567 USD.
0 · Reply
Shagg85
Shagg85 May. 11 at 2:17 PM
$NUVB how?
0 · Reply
searchthealley
searchthealley May. 11 at 2:13 PM
$NUVB gjbiostockgj
0 · Reply
Astrid00
Astrid00 May. 11 at 1:48 PM
$LXEO $LXRX $MLTX $NUVB
0 · Reply
Astrid00
Astrid00 May. 11 at 1:42 PM
$LXEO $LXRX $MLTX $NUVB
0 · Reply
FlyingChemist01
FlyingChemist01 May. 11 at 1:39 PM
$MLTX $NUVB $LXEO $LXRX today is a party 🎉🎉🎉
0 · Reply
y2says
y2says May. 11 at 12:27 AM
$MLTX why am I thinking 15% plus tomorrow? $NUVB
0 · Reply
Latest News on NUVB
Nuvation Bio: FDA accepts sNDA with updated data for IBTROZI

2026-05-07T06:20:14.000Z - 6 days ago

Nuvation Bio: FDA accepts sNDA with updated data for IBTROZI

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer

May 6, 2026, 8:00 AM EDT - 7 days ago

Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio to Participate in Upcoming Investor Conferences

May 5, 2026, 4:05 PM EDT - 7 days ago

Nuvation Bio to Participate in Upcoming Investor Conferences

Nuvation Bio Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 8 days ago

Nuvation Bio Earnings Call Transcript: Q1 2026

Nuvation Bio reports Q1 EPS 1c, consensus 5c

2026-05-04T20:17:35.000Z - 8 days ago

Nuvation Bio reports Q1 EPS 1c, consensus 5c

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

May 4, 2026, 4:10 PM EDT - 8 days ago

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

Apr 27, 2026, 8:00 AM EDT - 16 days ago

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers

Nuvation Bio reports results from TRUST-I and TRUST-II trials for IBTROZI

2026-04-21T22:05:15.000Z - 21 days ago

Nuvation Bio reports results from TRUST-I and TRUST-II trials for IBTROZI

Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

Apr 21, 2026, 6:00 PM EDT - 21 days ago

Nuvation Bio Announces IBTROZI® (Taletrectinib) Showed Highly Durable Responses in Longer-Term Follow-up Data from Pivotal Studies Presented at AACR 2026

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

Apr 20, 2026, 4:05 PM EDT - 22 days ago

Nuvation Bio to Report First Quarter 2026 Financial Results and Provide Business Update on May 4, 2026

Nuvation Bio amends license agreement for safusidenib with Daiichi Sankyo

2026-04-01T12:16:16.000Z - 6 weeks ago

Nuvation Bio amends license agreement for safusidenib with Daiichi Sankyo

Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo

Apr 1, 2026, 8:00 AM EDT - 6 weeks ago

Nuvation Bio Announces Acquisition of Japan Rights to Safusidenib from Daiichi Sankyo

Nuvation Bio and Eisai’s MAA for taletrectinib in NSLC accepted in Europe

2026-03-26T20:10:15.000Z - 6 weeks ago

Nuvation Bio and Eisai’s MAA for taletrectinib in NSLC accepted in Europe

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

Mar 26, 2026, 4:05 PM EDT - 6 weeks ago

Eisai and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency

Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026

Mar 17, 2026, 4:35 PM EDT - 2 months ago

Nuvation Bio to Present Pivotal IBTROZI® (Taletrectinib) Data in TKI-Naïve and TKI-Pretreated Patients with Advanced ROS1-Positive Non-Small Cell Lung Cancer at AACR 2026

Nuvation Bio Transcript: The Citizens Life Sciences Conference 2026

Mar 11, 2026, 8:25 AM EDT - 2 months ago

Nuvation Bio Transcript: The Citizens Life Sciences Conference 2026

Nuvation Bio falls -25.3%

2026-03-04T17:05:33.000Z - 2 months ago

Nuvation Bio falls -25.3%

Nuvation Bio Transcript: TD Cowen 46th Annual Health Care Conference

Mar 4, 2026, 10:30 AM EST - 2 months ago

Nuvation Bio Transcript: TD Cowen 46th Annual Health Care Conference

Nuvation Bio falls -25.3%

2026-03-04T15:08:39.000Z - 2 months ago

Nuvation Bio falls -25.3%

Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Mar 4, 2026, 8:30 AM EST - 2 months ago

Nuvation Bio Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses

Nuvation Bio falls -25.6%

2026-03-03T17:00:18.000Z - 2 months ago

Nuvation Bio falls -25.6%

Nuvation Bio falls -26.1%

2026-03-03T15:06:52.000Z - 2 months ago

Nuvation Bio falls -26.1%

Nuvation Bio price target raised to $13 from $12 at RBC Capital

2026-03-03T13:58:48.000Z - 2 months ago

Nuvation Bio price target raised to $13 from $12 at RBC Capital

Nuvation Bio price target lowered to $7 from $10 at UBS

2026-03-03T13:50:03.000Z - 2 months ago

Nuvation Bio price target lowered to $7 from $10 at UBS

Nuvation Bio Earnings Call Transcript: Q4 2025

Mar 2, 2026, 4:30 PM EST - 2 months ago

Nuvation Bio Earnings Call Transcript: Q4 2025

Nuvation Bio reports Q4 EPS (11c), consensus (5c)

2026-03-02T21:11:34.000Z - 2 months ago

Nuvation Bio reports Q4 EPS (11c), consensus (5c)

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Mar 2, 2026, 4:05 PM EST - 2 months ago

Nuvation Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026

Feb 17, 2026, 4:05 PM EST - 3 months ago

Nuvation Bio to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 2, 2026

Nuvation Bio finalizes protocol amendment for study of safusidenib

2026-02-09T13:05:20.000Z - 3 months ago

Nuvation Bio finalizes protocol amendment for study of safusidenib

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma

Feb 9, 2026, 8:00 AM EST - 3 months ago

Nuvation Bio Announces Pivotal Global Phase 3 SIGMA Trial (G203) for Safusidenib in IDH1-Mutant Glioma

Nuvation Bio price target raised to $13 from $11 at Truist

2026-01-27T13:28:11.000Z - 3 months ago

Nuvation Bio price target raised to $13 from $11 at Truist

These 20 stocks are strong choices for momentum investors

Jan 22, 2026, 10:26 AM EST - 3 months ago

These 20 stocks are strong choices for momentum investors

BE CELC COGT FBYD FRGE INBX KOD

Nuvation Bio price target raised to $12 from $9 at RBC Capital

2026-01-21T11:41:04.000Z - 4 months ago

Nuvation Bio price target raised to $12 from $9 at RBC Capital

Nuvation Bio Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 6:45 PM EST - 4 months ago

Nuvation Bio Transcript: 44th Annual J.P. Morgan Healthcare Conference

Nuvation Bio shares attractive on weakness, says B. Riley

2026-01-13T13:10:28.000Z - 4 months ago

Nuvation Bio shares attractive on weakness, says B. Riley

Nuvation Bio falls -17.3%

2026-01-12T15:06:02.000Z - 4 months ago

Nuvation Bio falls -17.3%

Nuvation Bio price target lowered to $17 from $18 at H.C. Wainwright

2026-01-12T13:56:01.000Z - 4 months ago

Nuvation Bio price target lowered to $17 from $18 at H.C. Wainwright

Nuvation Bio, Eisai enter exclusive taletrectinib license agreement

2026-01-12T13:06:37.000Z - 4 months ago

Nuvation Bio, Eisai enter exclusive taletrectinib license agreement

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 8:00 AM EST - 4 months ago

Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

Jan 12, 2026, 7:30 AM EST - 4 months ago

Nuvation Bio and Eisai Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside U.S., China and Japan

Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 6, 2026, 4:05 PM EST - 4 months ago

Nuvation Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

Dec 6, 2025, 10:40 PM EST - 5 months ago

Innovent Announces Inclusion of Seven Innovative Drugs including TYVYT New Indication and SYCUME in China's National Reimbursement Drug List

Nuvation Bio Transcript: Citi Annual Global Healthcare Conference 2025

Dec 3, 2025, 9:00 AM EST - 5 months ago

Nuvation Bio Transcript: Citi Annual Global Healthcare Conference 2025

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

Dec 3, 2025, 8:00 AM EST - 5 months ago

Nuvation Bio Announces Publication of Positive Phase 2 Study Results for Safusidenib for the Treatment of Grade 2 IDH1-Mutant Glioma in Neuro-Oncology

Nuvation Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 9:35 AM EST - 5 months ago

Nuvation Bio Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nuvation Bio Transcript: Jefferies London Healthcare Conference 2025

Nov 19, 2025, 10:00 AM EST - 6 months ago

Nuvation Bio Transcript: Jefferies London Healthcare Conference 2025

Nuvation Bio Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 6 months ago

Nuvation Bio Earnings Call Transcript: Q3 2025

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 3, 2025, 4:05 PM EST - 6 months ago

Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Oct 23, 2025, 7:30 AM EDT - 7 months ago

Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

Oct 20, 2025, 4:05 PM EDT - 7 months ago

Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Sep 30, 2025, 7:30 AM EDT - 8 months ago

Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer

Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Sep 19, 2025, 7:30 AM EDT - 8 months ago

Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Nuvation Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 9, 2025, 11:30 AM EDT - 8 months ago

Nuvation Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

Sep 7, 2025, 6:00 AM EDT - 8 months ago

Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer

Nuvation Bio Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 2:10 PM EDT - 8 months ago

Nuvation Bio Transcript: Cantor Global Healthcare Conference 2025

Nuvation Bio Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 9 months ago

Nuvation Bio Earnings Call Transcript: Q2 2025

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 7, 2025, 7:30 AM EDT - 9 months ago

Nuvation Bio Reports Second Quarter 2025 Financial Results and Provides Business Update

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Aug 5, 2025, 8:00 AM EDT - 10 months ago

Nuvation Bio To Present New Data on IBTROZI™ (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Jul 24, 2025, 4:05 PM EDT - 10 months ago

Nuvation Bio to Report Second Quarter 2025 Financial Results and Provide Business Update on August 7, 2025

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

Jun 24, 2025, 7:00 AM EDT - 11 months ago

Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI™) as Preferred Option to Clinical Practice Guidelines in Oncology for Advanced ROS1+ Non-Small Cell Lung Cancers

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

Jun 16, 2025, 7:30 AM EDT - 11 months ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for IBTROZI™ (taletrectinib), Manufactured by Nuvation Bio Inc.

Nuvation Bio Transcript: FDA Announcement

Jun 12, 2025, 7:30 AM EDT - 11 months ago

Nuvation Bio Transcript: FDA Announcement

US FDA approves Nuvation Bio's lung cancer therapy

Jun 11, 2025, 1:45 PM EDT - 11 months ago

US FDA approves Nuvation Bio's lung cancer therapy

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

Jun 11, 2025, 1:20 PM EDT - 11 months ago

U.S. Food and Drug Administration Approves Nuvation Bio's IBTROZI™ (taletrectinib), a Next-Generation Oral Treatment for Advanced ROS1-Positive Non-Small Cell Lung Cancer

Nuvation Bio Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

May 28, 2025, 3:30 PM EDT - 1 year ago

Nuvation Bio Transcript: TD Cowen's 6th Annual Oncology Innovation Summit

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

May 21, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio To Present New Data from Pivotal Clinical Studies of Taletrectinib in Advanced ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2025 Annual Meeting

Nuvation Bio Transcript: RBC Capital Markets Global Healthcare Conference 2025

May 21, 2025, 1:35 PM EDT - 1 year ago

Nuvation Bio Transcript: RBC Capital Markets Global Healthcare Conference 2025

Nuvation Bio Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

May 20, 2025, 3:00 PM EDT - 1 year ago

Nuvation Bio Transcript: H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

May 13, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Entrectinib at ISPOR 2025

Nuvation Bio Transcript: The Citizens JMP Life Sciences Conference 2025

May 8, 2025, 10:00 AM EDT - 1 year ago

Nuvation Bio Transcript: The Citizens JMP Life Sciences Conference 2025

Nuvation Bio Earnings Call Transcript: Q1 2025

May 7, 2025, 4:30 PM EDT - 1 year ago

Nuvation Bio Earnings Call Transcript: Q1 2025

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio Reports First Quarter 2025 Financial Results and Provides Business Update

Nuvation Bio to Present at The Citizens Life Sciences Conference

May 1, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio to Present at The Citizens Life Sciences Conference

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

Apr 22, 2025, 4:05 PM EDT - 1 year ago

Nuvation Bio to Report Results for First Quarter 2025 and Provide Business Update on May 7, 2025

Nuvation Bio Transcript: Jones Healthcare And Technology Innovation Conference

Apr 9, 2025, 1:00 PM EDT - 1 year ago

Nuvation Bio Transcript: Jones Healthcare And Technology Innovation Conference

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Nuvation Bio to Present at the Jones Healthcare and Technology Innovation Conference

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

Mar 25, 2025, 4:45 PM EDT - 1 year ago

Nuvation Bio to Present New Nonclinical Data for Taletrectinib at the American Association for Cancer Research Annual Meeting 2025

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Mar 25, 2025, 8:00 AM EDT - 1 year ago

Nuvation Bio to Present Matching-adjusted Indirect Comparison Data for Taletrectinib vs. Crizotinib During Mini Oral Presentation at the European Lung Cancer Congress 2025

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Mar 6, 2025, 4:30 PM EST - 1 year ago

Nuvation Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Nuvation Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 3:10 PM EST - 1 year ago

Nuvation Bio Transcript: TD Cowen 45th Annual Healthcare Conference

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Mar 3, 2025, 8:35 AM EST - 1 year ago

Nuvation Bio Secures Up to $250 Million in Non-Dilutive Financings from Sagard Healthcare Partners

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Feb 24, 2025, 8:00 AM EST - 1 year ago

Nuvation Bio to Present at the TD Cowen 45th Annual Health Care Conference

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

Feb 3, 2025, 8:00 AM EST - 1 year ago

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

Nuvation Bio Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 12:00 PM EST - 1 year ago

Nuvation Bio Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 6, 2025, 4:05 PM EST - 1 year ago

Nuvation Bio to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Jan 6, 2025, 8:00 AM EST - 1 year ago

Nuvation Bio Receives Approval from China's National Medical Products Administration for Taletrectinib for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

Jan 2, 2025, 7:00 PM EST - 1 year ago

Innovent Announces Second New Drug Application of DOVBLERON ® (Taletrectinib Adipate Capsule, ROS1 Inhibitor) was Approved by China's National Medical Products Administration

Bio_Invest101
Bio_Invest101 May. 11 at 6:59 PM
$NUVB Connor, Clark & Lunn Investment Management Ltd. reports 529.05% increase in ownership of NUVB / Nuvation Bio Inc. On May 11, 2026 - Connor, Clark & Lunn Investment Management Ltd. filed a 13F-HR form disclosing ownership of 1,207,771 shares of Nuvation Bio Inc. (US:NUVB) valued at $5,181,338 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 10, 2026 disclosing 191,998 shares of Nuvation Bio Inc.. This represents a change in shares of 529.05% during the quarter. The current value of the position is $5,785,223 USD.
0 · Reply
SNOB_ORDER
SNOB_ORDER May. 11 at 6:23 PM
$NUVB Short Interest update (+330K) From 50,296,748 to 50,622,584
1 · Reply
Stevekill
Stevekill May. 11 at 4:59 PM
What’s up with this? $NUVB https://www.prnewswire.com/news-releases/shareholder-alert-purcell--lefkowitz-llp-announces-shareholder-investigation-of-nuvation-bio-inc-nyse-nuvb-302765701.html
2 · Reply
Bio_Invest101
Bio_Invest101 May. 11 at 2:56 PM
$NUVB again small but high percentage by a bank Citigroup Inc reports 400.58% increase in ownership of NUVB / Nuvation Bio Inc. On May 11, 2026 - Citigroup Inc filed a 13F-HR form disclosing ownership of 315,776 shares of Nuvation Bio Inc. (US:NUVB) valued at $1,354,679 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 13, 2026 disclosing 63,082 shares of Nuvation Bio Inc.. This represents a change in shares of 400.58% during the quarter. The current value of the position is $1,512,567 USD.
0 · Reply
Shagg85
Shagg85 May. 11 at 2:17 PM
$NUVB how?
0 · Reply
searchthealley
searchthealley May. 11 at 2:13 PM
$NUVB gjbiostockgj
0 · Reply
Astrid00
Astrid00 May. 11 at 1:48 PM
$LXEO $LXRX $MLTX $NUVB
0 · Reply
Astrid00
Astrid00 May. 11 at 1:42 PM
$LXEO $LXRX $MLTX $NUVB
0 · Reply
FlyingChemist01
FlyingChemist01 May. 11 at 1:39 PM
$MLTX $NUVB $LXEO $LXRX today is a party 🎉🎉🎉
0 · Reply
y2says
y2says May. 11 at 12:27 AM
$MLTX why am I thinking 15% plus tomorrow? $NUVB
0 · Reply
Bio_Invest101
Bio_Invest101 May. 9 at 2:45 AM
$NUVB weekend read about our competitor in the same field. Let’s hear from Dr Hung in the 3 conferences in May https://stocks.apple.com/AdK38NZT0SRaJna_1N-lCoA
0 · Reply
Bio_Invest101
Bio_Invest101 May. 8 at 9:44 PM
$NUVB smalll but high percentage Gsa Capital Partners Llp reports 3,413.51% increase in ownership of NUVB / Nuvation Bio Inc. On May 8, 2026 - Gsa Capital Partners Llp filed a 13F-HR form disclosing ownership of 495,792 shares of Nuvation Bio Inc. (US:NUVB) valued at $2,126,948 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 6, 2026 disclosing 14,111 shares of Nuvation Bio Inc.. The current value of the position is $2,384,760 USD. Russell Investments Group, Ltd. reports 986.44% increase in ownership of NUVB / Nuvation Bio Inc. On May 8, 2026 - Russell Investments Group, Ltd. filed a 13F-HR form disclosing ownership of 265,700 shares of Nuvation Bio Inc. (US:NUVB) valued at $1,139,853 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 24,456 shares of Nuvation Bio Inc.. This represents a change in shares of 986.44% during the quarter.
0 · Reply
Bio_Invest101
Bio_Invest101 May. 8 at 9:40 PM
$NUVB after internal rules changes finalized here are Vanguard ownership Vanguard Capital Management Llc ownership in NUVB / Nuvation Bio Inc. On May 8, 2026 - Vanguard Capital Management Llc filed a 13F-HR form disclosing ownership of 11,626,198 shares of Nuvation Bio Inc. (US:NUVB) valued at $49,876,389 USD as of March 31, 2026. On May 8, 2026 - Vanguard Portfolio Management Llc filed a 13F-HR form disclosing ownership of 2,275,446 shares of Nuvation Bio Inc. (US:NUVB) valued at $9,761,663 USD as of March 31, 2026. On May 8, 2026 - Vanguard Fiduciary Trust Co filed a 13F-HR form disclosing ownership of 1,592,449 shares of Nuvation Bio Inc. (US:NUVB) valued at $6,831,606 USD as of March 31, 2026.
1 · Reply
HseklA
HseklA May. 8 at 8:16 PM
$NUVB Half of Patients With Advanced Lung Cancer Don’t Get Treatment, Study Finds New drugs have made America’s deadliest cancer more treatable than ever. So why aren’t they reaching patients? https://www.nytimes.com/2026/05/07/well/metastatic-lung-cancer-study.html
1 · Reply
Shagg85
Shagg85 May. 8 at 4:41 PM
$NUVB can someone explain why we are down over 2% today?
3 · Reply
Bio_Invest101
Bio_Invest101 May. 8 at 4:15 AM
$NUVB Holding On May 7, 2026 - Dimensional Fund Advisors Lp filed a 13F-HR form disclosing ownership of 2,052,691 shares of Nuvation Bio Inc. (US:NUVB) valued at $8,806,044 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 2,066,360 shares of Nuvation Bio Inc.. This represents a change in shares of -0.66% during the quarter. The current value of the position is $9,873,444 USD.
0 · Reply
Shagg85
Shagg85 May. 8 at 1:44 AM
$CAPR come on over to $NUVB nothing but good news and proven FDA approved ibtrozi best in class lung cancer drug. With another soon to be approved safusidenib for high grade IDH1 mutant giloma. Proven CEO Dr. David Hung who sold his last biotech for 14B
2 · Reply
Bio_Invest101
Bio_Invest101 May. 7 at 6:47 PM
$NUVB 2 M&A deals announced today, 5 total in first 7 days of May! Too hot for M&A in biotech sector. This one is related to cancer oncology diagnosis to offer better tailored treatment regimens. Sounds like relevant to help doctors in community centers to drop off the old SOC with less efficacy, no CNS brain penetrations drugs for novel long durability and high efficacy drug in Ibtrozi. Simply put the community centers need quick adoption of NCCN recommendations to save and improve cancer patients’ lives. Roche Diagnostics CEO Matt Sause said the company plans to combine PathAI’s digital pathology tools with Roche’s oncology diagnosis platforms. “Digital pathology has the potential to improve precision diagnosis of cancer and enable physicians to offer better tailored treatment regimens,” Sause said in a statement. https://www.medtechdive.com/news/roche-to-acquire-digital-pathology-firm-pathai-for-up-to-105b/819589/
0 · Reply
jstnfstr
jstnfstr May. 7 at 5:12 PM
$NUVB XBI now down 5.20. Hitting NUVB even worse than many others.
1 · Reply
jstnfstr
jstnfstr May. 7 at 4:28 PM
$NUVB XBI down 4.27. Tumbling since the open.
0 · Reply
BIOVIC
BIOVIC May. 7 at 3:00 PM
$NUVB 🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀🚀
0 · Reply
BIOVIC
BIOVIC May. 7 at 2:51 PM
$APP $NUVB 🚀🚀🚀🚀🚀🚀🚀
0 · Reply